Stifel Financial Corp Boosts Holdings in Repligen Co. (NASDAQ:RGEN)

Stifel Financial Corp grew its position in Repligen Co. (NASDAQ:RGEN) by 5.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,404 shares of the biotechnology company’s stock after acquiring an additional 226 shares during the quarter. Stifel Financial Corp’s holdings in Repligen were worth $655,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Quantinno Capital Management LP grew its holdings in Repligen by 10.9% during the 3rd quarter. Quantinno Capital Management LP now owns 1,957 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 193 shares during the last quarter. Quarry LP boosted its position in shares of Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares during the period. Point72 DIFC Ltd purchased a new position in shares of Repligen during the third quarter valued at approximately $3,227,000. Point72 Asset Management L.P. grew its stake in shares of Repligen by 3.0% during the third quarter. Point72 Asset Management L.P. now owns 324,434 shares of the biotechnology company’s stock valued at $48,282,000 after buying an additional 9,387 shares during the last quarter. Finally, Polar Asset Management Partners Inc. purchased a new stake in shares of Repligen in the third quarter worth approximately $580,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on RGEN shares. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a report on Thursday, December 19th. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $185.20.

Repligen Price Performance

Shares of RGEN opened at $146.95 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a 50 day moving average price of $144.27 and a 200-day moving average price of $141.66. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The stock has a market capitalization of $8.23 billion, a PE ratio of -397.15, a PEG ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. During the same quarter in the prior year, the business earned $0.23 earnings per share. Repligen’s revenue was up 9.7% on a year-over-year basis. Equities analysts predict that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.